## jiecan Zhou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3850079/publications.pdf Version: 2024-02-01



ILECAN ZHOLL

#	Article	IF	CITATIONS
1	The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovascular Diabetology, 2022, 21, .	6.8	51
2	Double Signal Amplification Strategy for Dual-Analyte Fluorescent Aptasensors for Visualizing Cancer Biomarker Proteins. Analytical Chemistry, 2022, 94, 10451-10461.	6.5	7
3	Fas-Associated Factor 1 Promotes Hepatic Insulin Resistance via JNK Signaling Pathway. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-10.	4.0	2
4	The Mechanisms and Animal Models of SARS-CoV-2 Infection. Frontiers in Cell and Developmental Biology, 2021, 9, 578825.	3.7	20
5	Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications. Cardiovascular Diabetology, 2021, 20, 9.	6.8	72
6	Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections. Frontiers in Pharmacology, 2020, 11, 592439.	3.5	24
7	Cause-specific risk of major adverse cardiovascular outcomes and hypoglycemic in patients with type 2 diabetes: a multicenter prospective cohort study. Endocrine, 2019, 63, 44-51.	2.3	8
8	Polytropic Influence of TRIB3 rs2295490 Genetic Polymorphism on Response to Antihypertensive Agents in Patients With Essential Hypertension. Frontiers in Pharmacology, 2019, 10, 236.	3.5	5
9	RasGRP1 is a target for VEGF to induce angiogenesis and involved in the endothelialâ€protective effects of metformin under high glucose in HUVECs. IUBMB Life, 2019, 71, 1391-1400.	3.4	11
10	Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes. Endocrine, 2019, 64, 536-543.	2.3	19